. 2021 Sep 16;21:131. doi: 10.1186/s12894-021-00897-2

Table 5.

Logistic regression analyses predicting probability of prostate cancer in subjects with tPSA 4–10 ng/mL

Predictors	AUC of individual predictor variable (95% CI); P value*	Bivariate analysis OR(95%CI); P value	Multivariate analysis
Age	0.63 (0.51–0.74) 0.235	1.069 (1.01–1.13); 0.031	1.081 *(1.02–1.15);0.013***	1.084 *(1.01–1.16);0.018***	1.084 *(1.01–1.16);0.018***
tPSA, ng/mL	0.50 (0.38–0.61) –	1.024 (0.76–1.38); 0.875	1.615 (0.66–3.86); 0.281	1.384 (0.49 − 3.88); 0.536	1.243 (0.44–3.48); 0.679
fPSA	0.59 (0.47–0.70) 0.418	0.529 (0.18–1.53); 0.240	0.038 (0.00–11.2); 0.261	0.070 (0.00–53.9); 0.433	0.071 (0.00–56.5); 0.437
%fPSA	0.63 (0.52–0.74) 0.090	0.961 (0.89–1.03); 0.284	1.155 (0.80–1.66); 0.448	1.108 (0.73–1.69); 0.631	1.108 (0.73–1.69); 0.632
p2PSA, pg/mL	0.59 (0.47–0.70) 0.286	1.023 (1.00–1.05); 0.089	–	–	–
%p2PSA	0.70 *(0.59–0.81)0.038***	1.020 (1.00–1.04); 0.007	–	1.022 *(1.01–1.04);0.007***	–
PHI	0.70 *(0.59–0.81)0.020***	1.743 (1.19–2.56); 0.005	–	–	1.760 *(1.17–2.64);0.006***
AUC of multivariate models (95% CI);	–	–	0.682 (0.57–0.78) *0.003*	0.784 (0.68–0.87) *< 0.001*	0.787 (0.68–0.87) *< 0.001*
Gain in predictive accuracy (95% CI); P value	–	–	–	0.102 (− 0.00–0.21); *0.054*	0.104 (0.00–0.21); *0.048*

Predictors

AUC of individual predictor variable (95% CI);
P value*

Bivariate analysis
OR(95%CI);
P value

Multivariate analysis

Base model **
OR (95%CI); P value

Base model + %p2PSA
OR (95% CI); P value

Base model + PHI
OR(95%CI); P value

Age

0.63

(0.51–0.74)

0.235

1.069

(1.01–1.13);

0.031

1.081

(1.02–1.15);0.013

1.084

(1.01–1.16);0.018

1.084

(1.01–1.16);0.018

tPSA, ng/mL

0.50

(0.38–0.61) –

1.024

(0.76–1.38); 0.875

1.615

(0.66–3.86); 0.281

1.384

(0.49 − 3.88); 0.536

1.243

(0.44–3.48); 0.679

fPSA

0.59

(0.47–0.70) 0.418

0.529

(0.18–1.53); 0.240

0.038

(0.00–11.2); 0.261

0.070

(0.00–53.9); 0.433

0.071

(0.00–56.5); 0.437

%fPSA

0.63

(0.52–0.74) 0.090

0.961

(0.89–1.03); 0.284

1.155

(0.80–1.66); 0.448

1.108

(0.73–1.69); 0.631

1.108

(0.73–1.69); 0.632

p2PSA, pg/mL

0.59

(0.47–0.70) 0.286

1.023

(1.00–1.05); 0.089

–

%p2PSA

0.70

(0.59–0.81)0.038

1.020

(1.00–1.04); 0.007

–

1.022

(1.01–1.04);0.007

–

PHI

0.70

(0.59–0.81)0.020

1.743

(1.19–2.56); 0.005

–

1.760

(1.17–2.64);0.006

AUC of multivariate models (95% CI);

–

0.682

(0.57–0.78)

0.003

0.784

(0.68–0.87)

< 0.001

0.787

(0.68–0.87)

< 0.001

Gain in predictive accuracy (95% CI);

P value

–

0.102

(− 0.00–0.21);

0.054

0.104

(0.00–0.21);

0.048

AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index; tPSA, total PSA, OR, odds ratio; CI, confidence interval

*P value: Comparison of AUC using tPSA as standard

**Base model includes age, tPSA, fPSA and %fPSA

P value to be statiscally significant with bolditalics